Art. -Nr.: HY-112861

Gln-AMS

Name: Gln-AMS
Brand: MedChemExpress
SKU: HY-112861
Price: 180.00 USD
Availability: InStock
Rating: 5 (3 reviews)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Gln-AMS is a potent inhibitor of Aminoacyl-tRNA Synthetase. Gln-AMS blocks the lactylation modification of downstream targets through competitive binding to AARS1, thereby regulating apoptosis, ferroptosis, and the transcriptional processes of related genes. Gln-AMS can be used in research on breast cancer, diabetic nephropathy, and sepsis-associated encephalopathy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.66%
CAS. Nr.: 209543-57-7
Formel: C₁₅H₂₂N₈O₈S
Molecular Weight:474.45

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Gln-AMS Chemical Structure

CAS. Nr.: 209543-57-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (7)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

AARS1

GlnRS

Cellular Effect

Cell Line	Type	Value	Description	References
PBMC	IC₅₀	0.8 μM Compound: GlnSA	Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction	[PMID: 18438987]

In Vitro

Gln-AMS (10 μM; 24 h) reduces global Kla, H3K79la, and H4K91la modification levels in breast cancer cells (MDA-MB-468 and T-47D)^[1].
Gln-AMS (1 μM; 72 h) decreased ACSL4 expression, increased GPX4 expression, reduced lipid peroxidation, restored mitochondrial membrane potential, decreased MDA and Fe2⁺ levels, and reduced mitochondrial superoxide levels in HGECs and HK-2 cells, thereby inhibiting ferroptosis^[2].
Gln-AMS (1 μM; 72 h) reversed high glucose-induced elevated expression of AARS1 and H3K18la and reversed cell death in human glomerular endothelial cells (HGECs) and human kidney tubular epithelial cells (HK-2)^[2].
Gln-AMS (1 μM; 72 h) decreased ELOVL5 protein and mRNA expression in HGECs and HK-2 cells^[2].
Gln-AMS (10 μM; 2 h) inhibits AARS1-mediated global protein lactylation and ATRIP lactylation in primary hippocampal neurons^[3].
Gln-AMS (10 μM; 12 h) inhibits Lactic acid (HY-B2227)-induced global protein lactylation and p-ATR, p-CHK1 expression in primary hippocampal neurons^[3].
Gln-AMS (10 μM; 12 h) inhibits p-ATR and p-CHK1 expression in HT22 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Real Time qPCR^[1]

View Protocol

Cell Line:

MDA-MB-468 and T-47D cells
Concentration:

10 μM
Incubation Time:

24 h
Result:

Decreased global Kla, H4K79la, and H4K91la levels.

Western Blot Analysis^[4]

View Protocol

Cell Line:

HT22
Concentration:

as indicated (Gln-AMS); 1 μg/mL (LPS); varying concentrations (lactate)
Incubation Time:

12 h
Result:

Modulated p-ATR (1989T) and p-CHK1 levels in LPS and lactate-treated HT22 cells.

Western Blot Analysis^[3]

View Protocol

Cell Line:

Primary hippocampal neurons
Concentration:

10 μM
Incubation Time:

2, 12 h
Result:

Inhibited overall protein lactylation and ATRIP lactylation in the cytoplasm. The product also decreased the expression of p-ATR and p-CHK1 induced by lactate.

Western Blot Analysis^[3]

View Protocol

Cell Line:

HT22
Concentration:

10 μM
Incubation Time:

12 h
Result:

Suppressed the expression of p-ATR and p-CHK1.

Chemical Information

CAS. Nr. 209543-57-7
Appearance Solid
Molecular Weight 474.45
Formel C₁₅H₂₂N₈O₈S
Color White to off-white
SMILES

NC1=C2N=CN([C@@H]3O[C@H](COS(=O)(NC([C@@H](N)CCC(N)=O)=O)=O)[C@@H](O)[C@H]3O)C2=NC=N1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]

2024 Oct;11(38):e2406333. PMID: 38981044
Cell Death Differ

AARS1-mediated lactylation of H3K18 and STAT1 promotes ferroptosis in diabetic nephropathy. [Abstract]

2025 Sep 23. PMID: 40987895
Brain Behav Immun

Targeting AARS1-dependent lactylation improves neuronal process plasticity and mitigates cognitive deficits in sepsis-associated encephalopathy. [Abstract]

2026 Jul:135:106493. PMID: 41713664

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (210.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1077 mL

10.5385 mL

21.0770 mL

5 mM

0.4215 mL

2.1077 mL

4.2154 mL

10 mM

0.2108 mL

1.0539 mL

2.1077 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Cell Biology Animals and Diseases Signal Pathway Related

Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Liu J, et al. H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer. Journal of experimental & clinical cancer research : CR. 2025 Aug 23;44(1):252. [Content Brief]

[2]. Hong J, et al. AARS1-mediated lactylation of H3K18 and STAT1 promotes ferroptosis in diabetic nephropathy. Cell death and differentiation. 2026 Mar;33(3):589-604. [Content Brief]

[3]. Luo S, et al. Targeting AARS1-dependent lactylation improves neuronal process plasticity and mitigates cognitive deficits in sepsis-associated encephalopathy. Brain, behavior, and immunity. 2026 Jul;135:106493. [Content Brief]

[4]. Escamilla Y, et al. Glutaminyl-tRNA Synthetase from Pseudomonas aeruginosa: Characterization, structure, and development as a screening platform. Protein science : a publication of the Protein Society. 2020 Apr;29(4):905-918.

[5]. Chênevert R, et al. Inhibitors of aminoacyl-tRNA synthetases as antibiotics and tools for structural and mechanistic studies. In: Lapointe J, Brakier-Gingras L, editors. Translation mechanisms. Georgetown (TX): Landes Bioscience; New York: Kluwer Academic/Plenum Publishers; 2003. p. 416-28.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1077 mL	10.5385 mL	21.0770 mL	52.6926 mL
	5 mM	0.4215 mL	2.1077 mL	4.2154 mL	10.5385 mL
	10 mM	0.2108 mL	1.0539 mL	2.1077 mL	5.2693 mL
	15 mM	0.1405 mL	0.7026 mL	1.4051 mL	3.5128 mL
	20 mM	0.1054 mL	0.5269 mL	1.0539 mL	2.6346 mL
	25 mM	0.0843 mL	0.4215 mL	0.8431 mL	2.1077 mL
	30 mM	0.0703 mL	0.3513 mL	0.7026 mL	1.7564 mL
	40 mM	0.0527 mL	0.2635 mL	0.5269 mL	1.3173 mL
	50 mM	0.0422 mL	0.2108 mL	0.4215 mL	1.0539 mL
	60 mM	0.0351 mL	0.1756 mL	0.3513 mL	0.8782 mL
	80 mM	0.0263 mL	0.1317 mL	0.2635 mL	0.6587 mL
	100 mM	0.0211 mL	0.1054 mL	0.2108 mL	0.5269 mL

Bioz

Keywords

Gln-AMS

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Gln-AMS

Publications Citing Use of MedChemExpress (MCE) Gln-AMS